🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 1 día
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 07/08/2008 | 31,30 | 31,47 | 28,27 | 28,97 | -8,15% | 10,22% | 4.018.100 |
| 06/08/2008 | 30,67 | 31,56 | 30,27 | 31,54 | +0,93% | 4,21% | 2.332.900 |
| 05/08/2008 | 30,50 | 31,25 | 30,49 | 31,25 | +4,34% | 2,49% | 2.828.800 |
| 04/08/2008 | 28,08 | 30,01 | 27,73 | 29,95 | -8,41% | 8,12% | 9.966.700 |
| 01/08/2008 | 33,09 | 34,58 | 32,60 | 32,70 | -5,22% | 5,98% | 4.275.700 |
| 31/07/2008 | 33,11 | 34,99 | 33,11 | 34,50 | +3,98% | 5,68% | 4.242.900 |
| 30/07/2008 | 32,97 | 33,35 | 31,31 | 33,18 | +0,51% | 6,19% | 2.066.100 |
| 29/07/2008 | 32,49 | 33,22 | 32,28 | 33,01 | +2,93% | 2,89% | 1.576.600 |
| 28/07/2008 | 32,35 | 33,61 | 31,81 | 32,07 | -1,57% | 5,56% | 2.003.800 |
| 25/07/2008 | 31,61 | 32,66 | 31,20 | 32,58 | +3,40% | 4,62% | 1.461.200 |
| 24/07/2008 | 32,57 | 32,89 | 31,43 | 31,51 | -3,82% | 4,48% | 3.005.100 |
| 23/07/2008 | 31,43 | 33,13 | 31,32 | 32,76 | +3,93% | 5,76% | 1.891.500 |
| 22/07/2008 | 31,64 | 31,99 | 30,88 | 31,52 | -0,63% | 3,51% | 1.865.200 |
| 21/07/2008 | 31,89 | 33,38 | 31,66 | 31,72 | -0,63% | 5,39% | 1.634.900 |
| 18/07/2008 | 32,40 | 32,59 | 31,64 | 31,92 | -1,97% | 2,93% | 2.600.300 |
| 17/07/2008 | 33,39 | 34,18 | 32,31 | 32,56 | -1,21% | 5,60% | 3.232.200 |
| 16/07/2008 | 32,05 | 33,54 | 31,87 | 32,96 | +2,26% | 5,21% | 2.226.700 |
| 15/07/2008 | 32,10 | 33,23 | 31,64 | 32,23 | -0,43% | 4,95% | 3.868.200 |
| 14/07/2008 | 33,52 | 33,61 | 32,12 | 32,37 | -2,47% | 4,45% | 2.067.800 |
| 11/07/2008 | 32,97 | 33,63 | 32,77 | 33,19 | -0,93% | 2,61% | 1.579.300 |
| 10/07/2008 | 33,67 | 33,67 | 32,68 | 33,50 | -0,50% | 2,94% | 1.950.000 |
| 09/07/2008 | 34,68 | 35,00 | 33,55 | 33,67 | -2,91% | 4,18% | 2.143.400 |
| 08/07/2008 | 32,90 | 34,68 | 32,73 | 34,68 | +4,87% | 5,93% | 1.771.800 |
| 07/07/2008 | 34,04 | 34,34 | 32,17 | 33,07 | -2,65% | 6,37% | 2.257.600 |
| 03/07/2008 | 34,31 | 34,41 | 33,09 | 33,97 | -0,18% | 3,85% | 1.282.600 |
| 02/07/2008 | 34,22 | 34,94 | 33,98 | 34,03 | -0,82% | 2,81% | 2.748.100 |
| 01/07/2008 | 33,35 | 34,47 | 32,86 | 34,31 | +2,51% | 4,83% | 3.175.200 |
| 30/06/2008 | 32,36 | 33,94 | 32,18 | 33,47 | +2,98% | 5,44% | 1.950.300 |
| 27/06/2008 | 32,39 | 32,76 | 31,90 | 32,50 | -0,21% | 2,66% | 2.030.200 |
| 26/06/2008 | 32,38 | 32,96 | 32,17 | 32,57 | -1,00% | 2,44% | 1.734.000 |